Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott Laboratories (ABT) raised its quarterly dividend to $0.63 for a 6.8% increase. Abbott has now increased dividends for 52 consecutive years. Abbott generated $6.35B in free cash flow during 2024 ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

Abbott Laboratories (ABT) raised its quarterly dividend to $0.63 with a 60.4% free cash flow payout ratio. Abbott’s FreeStyle Libre faces a Class I recall after 860 serious injuries and 7 deaths.

Malfunctioning glucose trackers made by Abbott Diabetes Care have been linked to more than 700 severe adverse events and seven potential deaths, the Food and Drug Administration (FDA) and Abbott said.

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...